Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment
Phase 3
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Registration Number
- NCT00213109
- Lead Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Brief Summary
The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type1 Diabetes Mellitus treated with insulin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Type1 Diabetes
- Criteria of postprandial glucose and HbA1c are met
Exclusion Criteria
- Type2 Diabetes
- Patients with antidiabetic drugs
- The other exclusion criteria are met
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Miglitol in managing Type 1 Diabetes Mellitus?
How does Miglitol compare to standard-of-care treatments for Type 1 Diabetes Mellitus in clinical efficacy?
What biomarkers are associated with response to Miglitol in Type 1 Diabetes Mellitus patients?
What are the known adverse events of Miglitol in Type 1 Diabetes Mellitus patients and how are they managed?
Are there any combination therapies or competitor drugs to Miglitol for managing Type 1 Diabetes Mellitus?